MICHAEL J GERBER, MD
Osteopathic Medicine in Denver, CO
License number
Colorado 25403
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
4200 E Ninth Ave, Denver, CO 80262
Phone
(303) 493-7000
Personal information
See more information about MICHAEL J GERBER at radaris.comName
Address
Phone
5100 W 126Th Cir, Broomfield, CO 80020
541 E 10Th St, Durango, CO 81301
424 Fairfax St, Denver, CO 80220
85 Stagecoach Cir, Carbondale, CO 81623
630 Dahlia St, Denver, CO 80220
Professional information
See more information about MICHAEL J GERBER at trustoria.com
Method For Treating A Pulmonary Hypertension Condition
Method For Treating A Pulmonary Hypertension Condition
US Patent:
2008013, Jun 12, 2008
Filed:
Dec 11, 2007
Appl. No.:
11/953955
Inventors:
Michael J. Gerber - Denver CO, US
Christopher Dufton - Nederland CO, US
Christopher Dufton - Nederland CO, US
International Classification:
A61K 31/505, A61P 9/12, A61P 9/00
US Classification:
514274
Abstract:
A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
Dr. Michael J Gerber, Denver CO - MD (Doctor of Medicine)
Dr. Michael J Gerber, Denver CO - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology
Address:
4200 E 9Th Ave, Denver 80262
(303) 493-7000 (Phone)
(303) 493-7000 (Phone)
Certifications:
Critical Care Medicine, 1991, Internal Medicine, 1982, Pulmonary Disease, 1986
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Colorado At Denver
Graduated: 1979
UCLA Hosp Clins
U Colo Hlth Sci Ctr
University of Colorado At Denver
Graduated: 1979
UCLA Hosp Clins
U Colo Hlth Sci Ctr
Method For Treating Resistant Hypertension
Method For Treating Resistant Hypertension
US Patent:
2007019, Aug 23, 2007
Filed:
Aug 24, 2006
Appl. No.:
11/509895
Inventors:
Michael J. Gerber - Denver CO, US
Richard J. Gorczynski - Westminster CO, US
Robert L. Roden - Broomfield CO, US
Richard J. Gorczynski - Westminster CO, US
Robert L. Roden - Broomfield CO, US
International Classification:
A61K 33/24, A61K 31/554, A61K 31/549, A61K 31/455, A61K 31/4184, A61K 31/41, A61K 31/401
US Classification:
424617, 514355, 514423, 514381, 5142235, 514471, 514571, 514412, 514651, 514278, 514738, 514411, 51421107
Abstract:
A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.
Method Of Stimulating Hematopoiesis With Hemoglobin
Method Of Stimulating Hematopoiesis With Hemoglobin
US Patent:
5631219, May 20, 1997
Filed:
Mar 8, 1994
Appl. No.:
8/208740
Inventors:
Gary J. Rosenthal - Boulder CO
Michael J. Gerber - Denver CO
Michael J. Gerber - Denver CO
Assignee:
Somatogen, Inc. - Boulder CO
International Classification:
A61K 3816, A01N 6100, A01N 102, G01N 3320
US Classification:
514 6
Abstract:
The present invention relates to a method for stimulating hematopoiesis in a mammal comprising administration of a therapeutically effective amount of a hemoglobin, including recombinant hemoglobin, and methods for treating cytopenias. These cytopenias include anemia, thrombocytopenia, lymphopenia, neutropenia and the like. The stimulation of hematopoiesis can occur both in vivo and ex vivo, as in the treatment of cytopenias associated with disease states, in cell culture or ex vivo expansion of bone marrow cells.
Stabilized Compositions Containing Hemoglobin
Stabilized Compositions Containing Hemoglobin
US Patent:
5914391, Jun 22, 1999
Filed:
Nov 17, 1997
Appl. No.:
8/913036
Inventors:
Michael J. Gerber - Denver CO
Douglas L. Looker - Lafayette CO
Bruce A. Kerwin - Lafayette CO
Douglas L. Looker - Lafayette CO
Bruce A. Kerwin - Lafayette CO
Assignee:
Baxter Biotech Technology Sarl - Neuchatel
International Classification:
A61K 3514, A61K 3806
US Classification:
530385
Abstract:
The present invention relates to hemoglobin compositions stabilized against the formation of aggregates. Such compositions contain at least a surfactant, said surfactant not being an adduct of a polymer and an anionic ligand. The present invention further relates to methods of making such hemoglobin compositions.
Methods And Reagents To Acquire Mri Signals And Images
Methods And Reagents To Acquire Mri Signals And Images
US Patent:
7097825, Aug 29, 2006
Filed:
Feb 25, 2002
Appl. No.:
10/082130
Inventors:
Michael Gerber - Denver CO, US
Assignee:
Allos Therapeutics, Inc. - Westminster CO
International Classification:
A61B 5/055
US Classification:
424 93, 424 933
Abstract:
Method for obtaining BOLD MRI images with allosteric effector compounds are disclosed. Methods for the determination of tumor oxygenation and for an optimal time for initiating radiation therapy are also disclosed.
Therapy For Complications Of Diabetes
Therapy For Complications Of Diabetes
US Patent:
2014007, Mar 13, 2014
Filed:
Nov 13, 2013
Appl. No.:
14/079464
Inventors:
- Wiesbaden, DE
Richard J. Gorczynski - Westminister CO, US
Michael J. Gerber - Denver CO, US
Richard J. Gorczynski - Westminister CO, US
Michael J. Gerber - Denver CO, US
International Classification:
A61K 31/4025, A61K 45/06
US Classification:
514 154, 514422, 51421207, 514221, 514392, 514307, 51421105, 514412, 514409, 51421103, 514381, 514397, 514382, 514394, 5142235, 514417, 51426631, 514415, 5142663, 514346
Abstract:
A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ET) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETreceptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETreceptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETreceptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETreceptor antagonist.
Medical Uses Of Allosteric Hemoglobin Modifier Compounds In Patient Care
Medical Uses Of Allosteric Hemoglobin Modifier Compounds In Patient Care
US Patent:
5677330, Oct 14, 1997
Filed:
Jun 7, 1995
Appl. No.:
8/478371
Inventors:
Donald J. Abraham - Midlothian VA
Michael Gerber - Denver CO
Michael Gerber - Denver CO
Assignee:
The Center for Innovative Technology - Herndon VA
Allos Therapeutics, Inc. - Denver CO
Allos Therapeutics, Inc. - Denver CO
International Classification:
A61K 3140, C07D20948, C07D22900
US Classification:
514421
Abstract:
A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in a wide variety of treatments including hypoxia, hypothermia, ischemia, stroke, ARDS, COPD, surgical blood loss, acute nonvolemic hemodilutions, wounds, diabetic ulcers, chronic leg ulcers, pressure sores, tissue transplants, and sepsis. The compounds are capable of acting on hemoglobin in whole blood.
Enoximone Formulations And Their Use In The Treatment Of Pde-Iii Mediated Diseases
Enoximone Formulations And Their Use In The Treatment Of Pde-Iii Mediated Diseases
US Patent:
2006029, Dec 28, 2006
Filed:
May 26, 2005
Appl. No.:
11/138894
Inventors:
Michael Gerber - Denver CO, US
Rick Gorczynski - Westminster CO, US
Michael Bristow - Englewood CO, US
Rick Gorczynski - Westminster CO, US
Michael Bristow - Englewood CO, US
International Classification:
A61K 31/4166, A61K 9/48
US Classification:
424451000, 514389000
Abstract:
The present invention provides pharmaceutical formulations of the drug enoximone for use in treatment of disease states in which inhibition of PDE-III may be beneficial.
Perinatal Treatment Of A Fetus To Avoid Oxygen Deprivation
Perinatal Treatment Of A Fetus To Avoid Oxygen Deprivation
US Patent:
5827888, Oct 27, 1998
Filed:
Oct 29, 1996
Appl. No.:
8/741174
Inventors:
Donald J. Abraham - Midlothian VA
Michael J. Gerber - Denver CO
Michael J. Gerber - Denver CO
Assignee:
The Center For Innovative Technology - Herndon VA
International Classification:
A61K 3119
US Classification:
514563
Abstract:
A method of using allosteric hemoglobin modifier compounds which promote the release of oxygen to improve delivery of oxygen from the mother to the fetus and the release of oxygen to tissues from fetal hemoglobin in treatment of maternal and fetal related syndromes.